today's Pick
Ebola vaccine trials being fast-tracked: researchers
Publish Date: Aug 28, 2014
Ebola vaccine trials being fast-tracked: researchers
Nigeria warns against complacency in Ebola fight A man reads a poster raising awareness on the Ebola virus reading "the risk of Ebola is still there. Let us apply the protective measures together" in Abidjian, Ivory Coast
  • mail
  • img
newvision

Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline -- which is developing the vaccine with the US National Institutes of Health (NIH) -- and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases. AFP  (NIAID). AFP

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
North Korea seeks joint probe into Sony hack
North Korea on Saturday called for a joint investigation with the United States into a crippling cyber attack on Sony Pictures, claiming it had means to prove Pyongyang had nothing to do with it....
Obama to N. Korea over Sony hack:
US President Barack Obama has warned North Korea it would face retaliation for a crippling cyber attack on Sony Pictures over an irreverent film comedy that infuriated Pyongyang....
Thug steals 30 bullets from prison guard
A thug stormed Maiha Prison and grabbed a magazine containing 30 bullets from a prison warder on guard....
Granddad defends petition to expel HIV-positive boy
The grandfather of a Chinese HIV-positive boy has defended his support for a petition to banish him from their village....
First Lady salutes Chameleone on memorable concert
Celebrated Ugandan musician Jose Chameleone took his fans down memory lane at the One Million Experience concert Thursday night at Kampala Serena Hotel....
Babu abused EALA MPs - impeachment report
The former speaker of the East African Legislative Assembly, Margaret Zziwa, was impeached for, among other reasons, allowing her husband to interfere with the operations of the assembly and issuing threats to members and staff....
Do you agree with the ban on the export of maids?
Yes
No
Can't Say
follow us
subscribe to our news letter